MEGAN GIBSON: Open Payments
NPI 1598423592 · OTTERBEIN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,416 in 100 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $709 · 2025 $2,416
Food & beverage: $2,316Education: $100
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $442 |
| ABBVIE INC. | 18 | $314 |
| Teva Pharmaceuticals USA, Inc. | 7 | $289 |
| Janssen Pharmaceuticals, Inc | 11 | $283 |
| Alkermes, Inc. | 12 | $259 |
| Axsome Therapeutics, Inc. | 6 | $207 |
| Tris Pharma Inc | 10 | $164 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $135 |
| Lundbeck LLC | 4 | $88 |
| Supernus Pharmaceuticals, Inc. | 2 | $52 |
Products named: REXULTI, VRAYLAR, Auvelity, Dyanavel XR, INVEGA SUSTENNA, UZEDY, ARISTADA, CAPLYTA.
Industry payments across IN — which companies pay providers there.
